BrainStorm Cell Therapeutics (BCLI.OB) – First Company to Receive Green Light from Israeli Ministry of Health for Stem-Cell Therapy in Israel
BrainStorm Cell Therapeutics Inc. develops adult stem cell technologies and therapeutics for the treatment of neurodegenerative diseases. The company today announced that the Israeli Ministry of Health (MOH) has granted clearance for a phase I/II clinical trial using BrainStorm’s autologous NurOwn™ stem cell therapy in patients with Lou Gehrig's disease. The clearance is an impressive milestone for BrainStorm, as it is the first company to receive clearance from the MOH for a differentiated stem cell-based therapy in Israel. "The Israeli Ministry of Health's clearance of our NurOwn clinical trial is one of BrainStorm's most significant accomplishments to date," Chaim Lebovits,…